Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

July 2016

P&T Committee Updates


At the June 6th, 2016 meeting, the Harvard Pilgrim Pharmacy & Therapeutics Committee reviewed four medications and decided the following.

P&T Committee Review and Decisions

Name

Description and Indication

Decision

Jardiance (empagliflozin) 

Jardiance is a sodium glucose cotransporter 2 (SGLT2) inhibitor used along with diet and exercise to improve glycemic control in people with type 2 diabetes.

  • Premium formulary: Added to preferred brand tier
  • Value formulary: Added to preferred brand tier
  • Medicare Advantage Formulary: Added to preferred brand tier

Osphena (ospemifene)

Osphena is a selective estrogen receptor modulator (SERM) indicated for treatment of moderate-to-severe dyspareunia due to vulvar and vaginal atrophy (VVA) of menopause.

  • Premium formulary: Continued coverage at non-preferred brand tier
  • Value formulary: Added to non-preferred brand tier
  • Medicare Advantage formulary: Continued coverage as enhanced benefit

Trulicity (dulaglutide)

Trulicity is a glucagon-like peptide-1 (GLP-1) receptor agonist used along with diet and exercise to improve glycemic control in adults with type 2 diabetes. 

  • Premium formulary: Added to preferred brand tier
  • Value formulary: Added to preferred brand tier 
  • Medicare Advantage formulary: Added to preferred brand tier

Veltassa (patiromer) 

Veltassa is a potassium binder indicated for the treatment of hyperkalemia (not to be used as an emergency treatment for life-threatening hyperkalemia due to its delayed onset of action).

  • Premium formulary: Continued coverage at non-preferred brand tier
  • Value formulary: Added to non-preferred brand tier
    Medicare Advantage Formulary:  Added to non-preferred brand tier

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

Substance Abuse Materials Now Available Online

CLINICIAN CORNER

Medical Policy Changes for Injectable and Infusible Drugs

Coverage of Vitamin B12 Screening and Testing

Coverage of Tumor Treatment Field Device for Glioblastoma

Briviact Covered With Prior Authorization

Nuplazid Covered With Prior Authorization

New Medical Policy for H. Pylori Testing

New Medical Policy for Nucala

Tier Increase for Apidra and Apidra SoloSTAR on the Premium Formulary

Tier Increase for Edecrin on the Premium Formulary

Diagnosing and Treating Depression in Older Adults

P&T Committee Meeting Update

Specialty Pharmacy Update

OFFICE ASSISTANT

Reminder: Keep Panel Status and Demographic Information Up to Date

PUBLICATION INFORMATION

Eric H. Schultz,
President and Chief Executive Officer

Robert Farias,
Vice President, Network Services

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Writer

Kristin Edmonston,
Production Coordinator